cognex corp. - CGNX
CGNX
Close Chg Chg %
67.38 -0.49 -0.73%
Closed Market
66.89
-0.49 (0.73%)
Volume: 2.38M
Last Updated:
Aug 7, 2026, 4:00 PM EDT
Company Overview: cognex corp. - CGNX
CGNX Key Data
| Open $68.39 | Day Range 66.79 - 70.14 |
| 52 Week Range 34.61 - 72.88 | Market Cap $11.22B |
| Shares Outstanding 166.42M | Public Float 165.80M |
| Beta 1.49 | Rev. Per Employee N/A |
| P/E Ratio 79.80 | EPS $0.85 |
| Yield 49.67% | Dividend $0.09 |
| EX-DIVIDEND DATE May 21, 2026 | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.99M |
CGNX Performance
| 1 Week | 2.53% | ||
| 1 Month | 0.13% | ||
| 3 Months | 1.87% | ||
| 1 Year | 63.51% | ||
| 5 Years | -18.52% |
CGNX Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
24
Full Ratings ➔
About cognex corp. - CGNX
Cognex Corp. engages in the provision of machine vision products and solutions that improve efficiency and quality in a wide range of businesses across attractive industrial end markets. It operates through the following geographical segments: the United States, Europe, Greater China, and Other. The company was founded by Robert J. Shillman, William Silver, and Marilyn Matz on January 7, 1981 and is headquartered in Natick, MA.
CGNX At a Glance
Cognex Corp.
One Vision Drive
Natick, Massachusetts 01760-2059
| Phone | 1-508-650-3000 | Revenue | 994.36M | |
| Industry | Electronic Equipment/Instruments | Net Income | 114.44M | |
| Sector | Electronic Technology | 2025 Sales Growth | 8.731% | |
| Fiscal Year-end | 12 / 2026 | Employees | 2,745 | |
| View SEC Filings |
CGNX Valuation
| P/E Current | 79.801 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 53.248 |
| Price to Sales Ratio | 6.128 |
| Price to Book Ratio | 4.027 |
| Price to Cash Flow Ratio | 24.82 |
| Enterprise Value to EBITDA | 30.169 |
| Enterprise Value to Sales | 5.867 |
| Total Debt to Enterprise Value | 0.013 |
CGNX Efficiency
| Revenue/Employee | 362,243.716 |
| Income Per Employee | 41,691.075 |
| Receivables Turnover | 5.935 |
| Total Asset Turnover | 0.496 |
CGNX Liquidity
| Current Ratio | 3.741 |
| Quick Ratio | 2.99 |
| Cash Ratio | 1.836 |
CGNX Profitability
| Gross Margin | 66.917 |
| Operating Margin | 16.349 |
| Pretax Margin | 18.384 |
| Net Margin | 11.509 |
| Return on Assets | 5.709 |
| Return on Equity | 7.606 |
| Return on Total Capital | 7.296 |
| Return on Invested Capital | 7.299 |
CGNX Capital Structure
| Total Debt to Total Equity | 5.133 |
| Total Debt to Total Capital | 4.883 |
| Total Debt to Total Assets | 3.798 |
| Long-Term Debt to Equity | 4.348 |
| Long-Term Debt to Total Capital | 4.136 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Cognex Corp. - CGNX
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 1.01B | 837.55M | 914.51M | 994.36M | |
Sales Growth
| -2.99% | -16.75% | +9.19% | +8.73% | |
Cost of Goods Sold (COGS) incl D&A
| 284.19M | 236.31M | 288.72M | 328.97M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 19.62M | 21.88M | 32.69M | 30.79M | |
Depreciation
| 16.35M | 17.27M | 21.27M | 20.29M | |
Amortization of Intangibles
| 3.27M | 4.61M | 11.42M | 10.50M | |
COGS Growth
| +2.49% | -16.85% | +22.18% | +13.94% | |
Gross Income
| 721.90M | 601.24M | 625.79M | 665.39M | |
Gross Income Growth
| -4.99% | -16.71% | +4.08% | +6.33% | |
Gross Profit Margin
| +71.75% | +71.79% | +68.43% | +66.92% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 453.24M | 478.54M | 510.73M | 502.83M | |
Research & Development
| 141.13M | 139.40M | 139.81M | 138.97M | |
Other SG&A
| 312.11M | 339.14M | 370.91M | 363.86M | |
SGA Growth
| +1.91% | +5.58% | +6.73% | -1.55% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 12.61M | 2.02M | (1.95M) | (1.37M) | |
EBIT after Unusual Expense
| 256.05M | 120.68M | 117.01M | 163.93M | |
Non Operating Income/Expense
| (5.36M) | 14.67M | 14.48M | 18.87M | |
Non-Operating Interest Income
| 6.90M | 16.05M | 13.98M | 16.79M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 250.69M | 135.35M | 131.49M | 182.80M | |
Pretax Income Growth
| -21.39% | -46.01% | -2.85% | +39.02% | |
Pretax Margin
| +24.92% | +16.16% | +14.38% | +18.38% | |
Income Tax
| 35.17M | 22.11M | 25.32M | 68.36M | |
Income Tax - Current - Domestic
| 54.04M | 32.63M | 32.53M | 9.02M | |
Income Tax - Current - Foreign
| 10.24M | 9.21M | 12.79M | 19.65M | |
Income Tax - Deferred - Domestic
| (49.13M) | (30.61M) | (23.60M) | 31.15M | |
Income Tax - Deferred - Foreign
| 20.01M | 10.89M | 3.59M | 8.55M | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 215.53M | 113.23M | 106.17M | 114.44M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 215.53M | 113.23M | 106.17M | 114.44M | |
Net Income Growth
| -22.99% | -47.46% | -6.24% | +7.79% | |
Net Margin Growth
| +21.42% | +13.52% | +11.61% | +11.51% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 215.53M | 113.23M | 106.17M | 114.44M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 215.53M | 113.23M | 106.17M | 114.44M | |
EPS (Basic)
| 1.2429 | 0.6574 | 0.6193 | 0.681 | |
EPS (Basic) Growth
| -21.64% | -47.11% | -5.80% | +9.96% | |
Basic Shares Outstanding
| 173.41M | 172.25M | 171.44M | 168.05M | |
EPS (Diluted)
| 1.2325 | 0.653 | 0.6151 | 0.6757 | |
EPS (Diluted) Growth
| -20.77% | -47.02% | -5.80% | +9.85% | |
Diluted Shares Outstanding
| 174.87M | 173.40M | 172.61M | 169.37M | |
EBITDA
| 288.29M | 144.58M | 147.75M | 193.36M | |
EBITDA Growth
| -14.04% | -49.85% | +2.19% | +30.87% | |
EBITDA Margin
| +28.65% | +17.26% | +16.16% | +19.45% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 77.211 | |
| Number of Ratings | 24 | Current Quarters Estimate | 0.374 | |
| FY Report Date | 09 / 2026 | Current Year's Estimate | 1.495 | |
| Last Quarter’s Earnings | 0.42 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 1.02 | Next Fiscal Year Estimate | 1.804 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 18 | 18 | 20 | 20 |
| Mean Estimate | 0.37 | 0.34 | 1.50 | 1.80 |
| High Estimates | 0.44 | 0.46 | 1.66 | 2.33 |
| Low Estimate | 0.31 | 0.28 | 1.41 | 1.65 |
| Coefficient of Variance | 8.26 | 11.12 | 4.99 | 9.50 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 12 | 12 | 13 |
| OVERWEIGHT | 4 | 4 | 4 |
| HOLD | 8 | 8 | 7 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Cognex Corp. - CGNX
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Cognex Corp. - CGNX
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Feb 20, 2026 | Marjorie T. Sennett Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | Matthew Moschner CEO & President; Director | 56,928 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 20, 2026 | Carl Gerst EVP, Vision & ID Products | 3,804 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $56.72 per share | 215,762.88 |
| Feb 20, 2026 | Carl Gerst EVP, Vision & ID Products | 5,570 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | Robert J. Willett Director | 56,659 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | Robert J. Willett Director | 23,120 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $56.72 per share | 1,311,366.40 |
| Feb 20, 2026 | Robert J. Willett Director | 29,969 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | Angelos Papadimitriou Director | 4,817 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 20, 2026 | Angelos Papadimitriou Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | Angelos Papadimitriou Director | 17,835 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | Marjorie T. Sennett Director | 4,817 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 20, 2026 | Tseng Chung Lee Director | 21,907 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | Marjorie T. Sennett Director | 23,023 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | Anthony Sun Director | 4,817 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 20, 2026 | Anthony Sun Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | Anthony Sun Director | 332,172 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | Sachin S. Lawande Director | 4,817 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 20, 2026 | Sachin S. Lawande Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | Sachin S. Lawande Director | 25,518 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | Tseng Chung Lee Director | 4,817 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |